000302883 001__ 302883
000302883 005__ 20250720021527.0
000302883 0247_ $$2doi$$a10.1038/s44355-025-00018-y
000302883 0247_ $$2pmid$$apmid:40626281
000302883 0247_ $$2pmc$$apmc:PMC7617876
000302883 0247_ $$2altmetric$$aaltmetric:176218223
000302883 037__ $$aDKFZ-2025-01423
000302883 041__ $$aEnglish
000302883 082__ $$a610
000302883 1001_ $$aDesert, Romain$$b0
000302883 245__ $$aImproving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.
000302883 260__ $$aSeoul$$bEd. Office of Gut and Liver$$c2025
000302883 3367_ $$2DRIVER$$aarticle
000302883 3367_ $$2DataCite$$aOutput Types/Journal article
000302883 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1752751197_14020$$xReview Article
000302883 3367_ $$2BibTeX$$aARTICLE
000302883 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302883 3367_ $$00$$2EndNote$$aJournal Article
000302883 520__ $$aHepatocellular carcinoma (HCC), the third cause of cancer-related deaths worldwide, continues to present significant therapeutic challenges. Despite significant therapeutic advancement in the last decade, the efficacy of systemic treatments for patients with advanced HCC remains unsatisfactory. While the clinical introduction of immune checkpoint inhibitors has improved response rates and overall survival, their clinical success remains still limited. Here we provide a comprehensive review of current and emerging strategies aimed at enhancing the efficacy of immunotherapy for the treatment of HCC. Both clinical studies conducted in patients as well as studies in preclinical models have markedly advanced our understanding of resistance as well as uncovered novel approaches to overcome resistance. Recent progress is paving the way for improved efficacy and safety of novel approaches that will improve the dismal prognosis of patients with advanced HCC.
000302883 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000302883 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302883 650_7 $$2NLM Chemicals$$aImmune Checkpoint Inhibitors
000302883 650_2 $$2MeSH$$aHumans
000302883 650_2 $$2MeSH$$aCarcinoma, Hepatocellular: therapy
000302883 650_2 $$2MeSH$$aCarcinoma, Hepatocellular: immunology
000302883 650_2 $$2MeSH$$aLiver Neoplasms: therapy
000302883 650_2 $$2MeSH$$aLiver Neoplasms: immunology
000302883 650_2 $$2MeSH$$aImmunotherapy: methods
000302883 650_2 $$2MeSH$$aImmune Checkpoint Inhibitors: therapeutic use
000302883 650_2 $$2MeSH$$aAnimals
000302883 650_2 $$2MeSH$$aDisease Models, Animal
000302883 7001_ $$aGianonne, Fabio$$b1
000302883 7001_ $$aSaviano, Antonio$$b2
000302883 7001_ $$aHoshida, Yujin$$b3
000302883 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b4$$udkfz
000302883 7001_ $$aNahon, Pierre$$b5
000302883 7001_ $$aBaumert, Thomas F$$b6
000302883 773__ $$0PERI:(DE-600)2536214-8$$a10.1038/s44355-025-00018-y$$gVol. 2, no. 1, p. 8$$n1$$p8$$tGut and liver$$v2$$x1976-2283$$y2025
000302883 909CO $$ooai:inrepo02.dkfz.de:302883$$pVDB
000302883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000302883 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000302883 9141_ $$y2025
000302883 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGUT LIVER : 2022$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-10-13T15:29:10Z
000302883 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-10-13T15:29:10Z
000302883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : single blind peer review$$d2023-10-13T15:29:10Z
000302883 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2023-10-13T15:29:10Z
000302883 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000302883 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000302883 9201_ $$0I:(DE-He78)D440-20160331$$kD440$$lChronische Entzündung und Krebs$$x0
000302883 980__ $$ajournal
000302883 980__ $$aVDB
000302883 980__ $$aI:(DE-He78)D440-20160331
000302883 980__ $$aUNRESTRICTED